HR Execs on the Move

ChemNavigator

www.chemnavigator.com

 
At ChemNavigator we help research organizations identify and procure the chemistry they need for drug discovery and agrochemical research. We serve researchers in medicinal, computational, and synthetic chemistry as well as chemical procurement
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Oncoceutics Pharmaceuticals Inc

Oncoceutics Pharmaceuticals Inc is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Shady Grove Adventist Hospital

Shady Grove Adventist Hospital is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Illumina

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina`s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

ARKAL MEDICAL INC

ARKAL MEDICAL INC is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.